Chromosomal imbalances revealed in primary renal cell carcinomas by comparative genomic hybridization.
Chromosomal imbalances revealed in primary renal cell carcinomas by comparative genomic hybridization. Int J Clin Exp Pathol. 2015;8(4):3636-47 Authors: Kang XL, Zou H, Pang LJ, Hu WH, Zhao J, Qi Y, Liu CX, Hu JM, Tang JX, Li HA, Liang WH, Yuan XL, Li F Abstract Renal cell carcinoma (RCC) accounts for approximately 3% of all new cancer cases. Although the classification of RCC is based mainly on histology, this method is not always accurate. We applied comparative genomic hybridization (CGH) to determine genomic alterations in 46 cases of different RCC histological subtypes [10 cases of clear cell RCC (CCRCC), 13 cases of papillary RCC (PRCC), 12 cases of chromophobe RCC (CRCC), 9 cases of Xp11.2 translocation RCC (Xp11.2RCC), 2 cases of undifferentiated RCC (unRCC)], and investigated the relationships between clinical parameters and genomic aberrations. Changes involving one or more regions of the genome were seen in all RCC patients; DNA sequence gains were most frequently (>30%) seen in chromosomes 7q, 16p, and 20q; losses from 1p, 3p, 13q, 14q, and 8p. We conclude CGH is a useful complementary method for differential diagnosis of RCC. Loss of 3p21-25, 15q, and gain of 16p11-13 are relatively particular to CCRCC vs. other types of RCC. Gain of 7p13-22, 8q21-24, and loss of 18q12-ter, 14q13-24, and Xp11-q13/Y are more apparent in PRCC, and gain of 8q21-24 is characteristic of type 2 PRCC vs. type 1 PRCC. Loss of 2q12-32, 10p12-15, and 11p11-15, 13p ...
CONCLUSIONS: Simultaneous CRC and CRLM resections seem to be safe when patients are carefully selected, also considering the risk of recurrence concerning oncologic outcomes. The pre-planning of simultaneous resection is mandatory to plan trocar positioning, procedure sequencing, and patient position. PMID: 32490901 [PubMed - in process]
Publication date: Available online 3 June 2020Source: Carbohydrate PolymersAuthor(s): Ben Newland, Carmine Varricchio, Yvonne Körner, Franziska Hoppe, Christian Taplan, Heike Newland, Dimitri Eigel, Giusy Tornillo, Dagmar Pette, Andrea Brancale, Petra B. Welzel, F. Philipp Seib, Carsten Werner
Publication date: Available online 3 June 2020Source: Carbohydrate PolymersAuthor(s): Zhuodong Chai, Chao Teng, Lei Yang, Lianjie Ren, Zhongyue Yuan, Siyuan Xu, Manman Cheng, Yanmei Wang, Zhen Yan, Chao Qin, Xiaopeng Han, Lifang Yin
CONCLUSION: a Navigation Program was developed adapted to the Brazilian reality, and attributions of the navigators were created. PMID: 32491120 [PubMed - in process]
Publication date: Available online 3 June 2020Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Houhe Liu, Yusi Quan, Xinlin Jiang, Xiaotian Zhao, Yi Zhou, Jijun Fu, Lingran Du, Xiaoya Zhao, Jing Zhao, Lu Liang, Di Yi, Yugang Huang, Guodong Ye
Publication date: Available online 3 June 2020Source: Sensors and Actuators B: ChemicalAuthor(s): Hui-Min Wang, Ai-Jun Wang, Pei-Xin Yuan, Jiu-Ju Feng
Chem. Commun., 2020, Accepted Manuscript DOI: 10.1039/D0CC03589K, CommunicationLongbing Ling, Haizhou Yu, Muhammad Ismail, Yan-Ping Zhu, Yuan Du, Junhui Qi An amphiphilic dimeric-podophyllotoxin (PODO) phospholipid was synthesized to assemble into liposomes as a combination of prodrug and nanocarriers. Results have demonstrated cell membrane-like delivery system possessed an improved cellular uptake... The content of this RSS Feed (c) The Royal Society of Chemistry
Authors: Cheng J, Yang A, Cheng S, Feng L, Wu X, Lu X, Zu M, Cui J, Yu H, Zou L Abstract BACKGROUND MicroRNAs (miRNAs) are attracting substantial interest as promising noninvasive biomarkers for gastric cancer (GC). Our study aimed to identify circulating miRNAs that are potential noninvasive markers for precancerous lesions and early gastric cancers (EGCs). MATERIAL AND METHODS Plasma specimens were obtained from 58 gastritis subjects, 54 patients with precancerous lesions, and 38 EGC patients for study. RESULTS Significant differences in the plasma expression levels of miR-19a-3p, miR-22-3p, miR-146a-5p, and miR-483-5p (all P
For example, does transporting patients with cancer from Site A to Site B count as clinical volunteer experience? This is assuming that the driver is in direct contact with the patients. What are some other examples of gaining clinical exposure that are unheard/unrealized of? This will greatly help students such as myself in their gap-years working in non-clinical jobs needing to gain more volunteer experience! For my particular case, I am seeking for an opportunity to gain ~80 hours... What are Some Examples of NonTraditional Ways of Earning Clinical Volunteer Experience?
Renal angiomyolipoma (AML) is the most common benign solid renal neoplasm seen in daily clinical practice, with an estimated prevalence of 0.2% to 0.6%.1 It is a triphasic mesenchymal neoplasm composed of varying amounts of dysmorphic vasculature, smooth muscle, and mature adipocytes. Pathologically, AML is now considered among the family of perivascular epithelioid cell tumors. Approximately 80% of cases are sporadic, with mean age at presentation being 43 years and most cases identified at fourth to sixth decades of life. There is also a strong female predilection, with female-to-male ratio of 4:1 in sporadic cases.1 Twe...